Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Weiner

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancer|December 8, 2015
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemiaJane E Churpek, Rafael Marquez, Barbara Neistadt, et al.
Archives of Neurology|October 12, 2005
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectationsElliot M Frohman, Olaf Stüve, Eva Havrdova, et al.
Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.
Multiple Sclerosis and Related Disorders|April 23, 2022
Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple SclerosisTamara B Kaplan, Arpita Gopal, Valerie J Block, et al.
Nature Communications|May 20, 2024
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Medrxiv : the Preprint Server for Health Sciences|July 18, 2023
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
Clinical Immunology (Orlando, Fla.)|July 6, 2023
Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosisTanuja Chitnis, John Foley, Carolina Ionete, et al.
Blood Advances|January 4, 2018
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLLSabah Kadri, Jimmy Lee, Carrie Fitzpatrick, et al.
Stereotactic and Functional Neurosurgery|April 16, 2023
An Initial Experience of Completion Hemispherotomy via Magnetic Resonance-Guided Laser Interstitial TherapyVijay M Ravindra, Lucia Ruggieri, Nisha Gadgil, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancer|December 8, 2015
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemiaJane E Churpek, Rafael Marquez, Barbara Neistadt, et al.
Archives of Neurology|October 12, 2005
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectationsElliot M Frohman, Olaf Stüve, Eva Havrdova, et al.
Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.
Multiple Sclerosis and Related Disorders|April 23, 2022
Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple SclerosisTamara B Kaplan, Arpita Gopal, Valerie J Block, et al.
Nature Communications|May 20, 2024
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Medrxiv : the Preprint Server for Health Sciences|July 18, 2023
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
Clinical Immunology (Orlando, Fla.)|July 6, 2023
Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosisTanuja Chitnis, John Foley, Carolina Ionete, et al.
Blood Advances|January 4, 2018
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLLSabah Kadri, Jimmy Lee, Carrie Fitzpatrick, et al.
Stereotactic and Functional Neurosurgery|April 16, 2023
An Initial Experience of Completion Hemispherotomy via Magnetic Resonance-Guided Laser Interstitial TherapyVijay M Ravindra, Lucia Ruggieri, Nisha Gadgil, et al.
Pageof 6